1 |
The effectiveness of xeljanz in rheumatoid arthritis patients |
- |
- |
- |
- |
046 [1] 46 💬 |
2 |
Tofacitinib (xeljanz) |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 [1] 46 💬 |
3 |
Tofacitinib (xeljanz®) |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 [1] 46 💬 |
4 |
Tofacitinib (xeljanz®) 11mg prolonged release tablet |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 [1] 46 💬 |
5 |
Tofacitinib 5 mg [xeljanz] |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 [2] 46, 50 💬 |
6 |
Tofacitinib 5mg [xeljanz] 1 year open-label extension |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
084 [1] 84 💬 |
7 |
Tofacitinib 5mg oral tablet [xeljanz] 16 week trial |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
084 [1] 84 💬 |
8 |
Xeljanz |
- |
- |
- |
- |
046 [3] 46, 97, 271 💬 |
9 |
Xeljanz 5 mg film-coated tablets |
- |
- |
- |
- |
046 [2] 46, 97 💬 |
10 |
Xeljanz 5mg |
- |
- |
- |
- |
046 [1] 46 💬 |
11 |
Xeljanz 5mg film-coated tablets |
- |
- |
- |
- |
097 [1] 97 💬 |
12 |
Xeljanz 5mg tablet |
- |
- |
- |
- |
046 [1] 46 💬 |